Concordance of PD-L1 Expression Detection in Non–Small Cell Lung Cancer (NSCLC) Tissue Biopsy Specimens Between OncoTect iO Lung Assay and Immunohistochemistry (IHC)

Young, Stephen; Griego-Fullbright, Christen; Wagner, Aaron; Chargin, Amanda; Patterson, Bruce K.; Chabot‐Richards, Devon

doi:10.1093/ajcp/aqy063

Cited by 7 publications

(6 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In NSCLC tumors, fewer macrophages and DCs were present in the TME compared with adjacent normal lung tissues which was consistent with previous research ( 10 ), indicating chronic inflammation or disrupted tumor homeostasis in these NSCLC patients. MDSCs are divided into polymorphonuclear (PMN) and monocytic (M) MDSCs ( 21 ).…”

Section: Discussionsupporting

confidence: 92%

“…For flow cytometry as described before ( 10 ), single cells from tumor tissues and paired adjacent normal tissues were washed and stained with Fixable Viability Stain 780 (BD Biosciences) for cell viability measurements. Then, cells were washed with stain buffer (BD Biosciences) and blocked with human Fc block (BD Biosciences) to block Fc receptors.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Tumor Immune Microenvironment Characteristics and Their Prognostic Value in Non-Small-Cell Lung Cancer

Xiong

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

IntroductionCancer progression is determined not only by the malignant behavior of tumors but also by the immune microenvironment. The tumor immune microenvironment also plays a pivotal role in determining the clinical response of non-small-cell lung cancer (NSCLC) to immunotherapies. To understand the possible mechanisms and explore new targets in lung cancer immunotherapy, we characterized the immune profiles in NSCLC patients.MethodsSeventy-one NSCLC patients who underwent radical resection were selected. The immune cell composition in paired tumor and adjacent normal lung tissues was tested by flow cytometry. The associations of tumor immune microenvironment characteristics with clinicopathological factors and overall survival were analyzed. Kaplan–Meier curves and Cox proportional hazards models were used to determine differences in survival.ResultsCompared with adjacent normal lung tissues, an increased proportion of CD45+ hematopoietic-derived cells, CD4+ T cell subtypes, Tregs and B cells was observed in tumor samples with a reduced frequency of myeloid cell populations. There was no significant increase in total CD8+ T cells, but both PD1+ and CD38+ CD8+ T cells were significantly enriched in tumor samples and statistically significantly associated with tumor size. In addition, positive CD38 expression was highly correlated with PD1 positivity. A high proportion of CD8+ T cells and a low percentage of PD1+ CD8+ T cells were statistically significantly associated with better survival in stage II and III patients, whereas a low frequency of CD38+ CD8+ T cells was statistically significantly associated with better survival in all patients and identified as an independent prognostic factor (p=0.049).ConclusionWe profiled the immune cells in the tumor tissues of NSCLC patients using flow cytometry. The results revealed significant enrichment of infiltrating immune cells. A strong correlation was identified between CD38 and PD-1 expression on CD8+ T cells in tumors. CD8+ T cells and their subtypes play a critical role in the prediction of prognosis.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Methodsmentioning

confidence: 99%

Tumor Immune Microenvironment Characteristics and Their Prognostic Value in Non-Small-Cell Lung Cancer

Xiong

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…In previous studies, the same methodology has been used to examined the PD-L1 expression on tumor cells and immune cells isolated from nonsmall lung cancer specimens [20,21]. They showed that the results of flow cytometric detection of PD-L1 were highly concordant with the results using IHC and proposed that the differential quantification of PD-L1 on tumor cells and immune cells may allow for better prediction of response to anti-PD-1/PD-L1 antibody therapy.…”

Section: Discussionmentioning

confidence: 96%

Flow cytometry detection of cell type-specific expression of programmed death receptor ligand-1 (PD-L1) in colorectal cancer specimens

Saito

Tojo

Kumagai

et al. 2021

Heliyon

View full text Add to dashboard Cite

“…Studies analyzing PD‐L1 testing on lung carcinoma cytology specimens originated mostly from the USA, followed by publications arising from Italy, Canada, United Kingdom, China, Germany, Japan, India, Turkey and other countries. The Dako clone 22C3 was the most common clone analyzed on cytology specimens, followed by the Ventana SP263 clone 17–67 . The data collected included the clone type used in each study.…”

Section: Resultsmentioning

confidence: 99%

Program death ligand‐1 immunocytochemistry in lung cancer cytological samples: A systematic review

Satturwar

Girolami

Munari

et al. 2022

Diagnostic Cytopathology

View full text Add to dashboard Cite

In this era of personalized medicine, targeted immunotherapies like immune checkpoint inhibitors (ICI) blocking the programmed death-1 (PD-1)/program death ligand-1 (PD-L1) axis have become an integral part of treating advanced stage non-small cell lung carcinoma (NSCLC) and many other cancer types. Multiple monoclonal antibodies are available commercially to detect PD-L1 expression in tumor cells by immunohistochemistry (IHC). As most clinical trials initially required tumor biopsy for PD-L1 detection by IHC, many of the currently available PD-1/PD-L1 assays have been developed and validated on formalin fixed tissue specimens. The majority (>50%) of lung cancer cases do not have a surgical biopsy or resection specimen available for ancillary testing and instead must rely primarily on fine needle aspiration biopsy specimens for diagnosis, staging and ancillary tests. Review of the literature shows multiple studies exploring the feasibility of PD-L1 IHC on cytological samples. In addition, there are studies addressing various aspects of IHC validation on cytology preparations including pre-analytical (e.g., different fixatives), analytical (e.g., antibody clone, staining platforms, inter and intra-observer agreement, cytology-histology concordance) and post-analytical (e.g., clinical outcome) issues. Although promising results in this field have emerged utilizing cytology samples, many important questions still need to be addressed. This review summarizes the literature of PD-L1 IHC in lung cytology specimens and provides practical tips for optimizing analysis.

show abstract

Concordance of PD-L1 Expression Detection in Non–Small Cell Lung Cancer (NSCLC) Tissue Biopsy Specimens Between OncoTect iO Lung Assay and Immunohistochemistry (IHC)

Abstract: The nonsubjective OncoTect iO Lung Assay has been shown to be at least as accurate and sensitive as IHC for the detection of PD-L1 expression while providing additional information to guide treatment.

Cited by 7 publications

References 20 publications

Tumor Immune Microenvironment Characteristics and Their Prognostic Value in Non-Small-Cell Lung Cancer

Tumor Immune Microenvironment Characteristics and Their Prognostic Value in Non-Small-Cell Lung Cancer

Flow cytometry detection of cell type-specific expression of programmed death receptor ligand-1 (PD-L1) in colorectal cancer specimens

Program death ligand‐1 immunocytochemistry in lung cancer cytological samples: A systematic review

Contact Info

Product

Resources

About